FX.co ★ Synopsys Issues Statement In Response To CMA's Provisional Acceptance Of Proposed Remedies

Synopsys (SNPS) has expressed satisfaction with the Competition and Markets Authority's (CMA) provisional acceptance of suggested remedies in Phase 1 concerning the proposed acquisition of Ansys (ANSS). Importantly, the transaction will not be moved to a more intensive Phase 2 scrutiny. The firm anticipates finalizing the transaction in the first half of 2025.

"We will uphold a constructive and cooperative dialogue with the CMA as it completes its evaluation process. Our customers remain strongly in favor of this acquisition," Synopsys noted.